SCHEMBL197041

SCHEMBL197041

Clc1ccc(Cl)c2[nH]cnc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 4/20 0.47
DYRK1A Q13627 3/20 0.46
AURKA O14965 2/20 0.46
DAPK3 O43293 2/20 0.46
PRKD3 O94806 2/20 0.46
MAP4K4 O95819 2/20 0.46
RET P07949 2/20 0.46
IGF1R P08069 2/20 0.46
PIM1 P11309 2/20 0.46
CLK2 P49760 2/20 0.46
GSK3A P49840 2/20 0.46
GSK3B P49841 2/20 0.46
PRKX P51817 2/20 0.46
BTK Q06187 2/20 0.46
TYRO3 Q06418 2/20 0.46
NTRK3 Q16288 2/20 0.46
TAOK1 Q7L7X3 2/20 0.46
CLK4 Q9HAZ1 2/20 0.46
ALK Q9UM73 2/20 0.46
ABL1 P00519 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13184288 0.83 CSNK2A1 (0.41) CSNK2A1DYRK1AAURKADAPK3PRKD3
SCHEMBL23227987 0.83 CSNK2A1 (0.41) CSNK2A1DYRK1AAURKADAPK3PRKD3
SCHEMBL6447653 0.83 CSNK2A1 (0.41) CSNK2A1DYRK1AAURKADAPK3PRKD3
SCHEMBL18225451 0.77 KDM5A (0.59) CSNK2A1DYRK1AAURKADAPK3PRKD3
SCHEMBL9755110 0.76 CSNK2A1 (0.40) CSNK2A1DYRK1AAURKADAPK3PRKD3
SCHEMBL6307133 0.73 CSNK2A1 (0.44) CSNK2A1DYRK1AAURKADAPK3PRKD3
SCHEMBL4535246 0.73 DPP4 (0.44) CSNK2A1DYRK1AAURKADAPK3PRKD3
SCHEMBL3167612 0.72 CCR1 (0.53) CSNK2A1DYRK1AAURKADAPK3PRKD3
SCHEMBL824416 0.70 CSNK2A1 (0.55) CSNK2A1DYRK1AAURKAABL1PRKACA
SCHEMBL17336412 0.70 IGF1R (0.60) CSNK2A1DYRK1AAURKADAPK3PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293905-B2 Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-23 US disclosed
US-8088883-B2 Transition metal complex and process for producing conjugated aromatic compound using the transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-20110046336-A1 TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX SUMITOMO CHEMICAL COMPANY, LIMITED 2011-02-24 US disclosed
US-20100292481-A1 METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED 2010-11-18 US disclosed
EP-2233459-A1 METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND Sumitomo Chemical Company, Limited (JP) 2010-09-29 EP disclosed
US-20100184978-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-07-22 US disclosed
EP-2192124-A1 TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND WITH THE TRANSITION METAL COMPLEX Sumitomo Chemical Company, Limited (JP) 2010-06-02 EP disclosed
EP-2172470-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX Sumitomo Chemical Company, Limited (JP) 2010-04-07 EP disclosed
US-20090326188-A1 Method for producing polyarylene SUMITOMO CHEMICAL COMPANY, LIMITED 2009-12-31 US disclosed
EP-2065420-A1 METHOD FOR PRODUCING POLYARYLENE Sumitomo Chemical Company, Limited (JP) 2009-06-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046336-A1 TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX C9, C5, AP1M1 CSNK2A1 3767/4885DYRK1A 4445/4885AURKA 341/4885
US-20100184978-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX C9, C5, AP2M1 CSNK2A1 3810/4885DYRK1A 3814/4885AURKA 635/4885
US-20100292481-A1 METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND TYR, PAH, AHR CSNK2A1 4323/4885DYRK1A 3271/4885AURKA 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.